Induction of G 2 / M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T 24 cells
C. Park,Gi-Young Kim,Gun-Do Kim,B. Choi,Yeong-Min Park,Yung-Hyun Choi
Abstract:Curcumin, a polyphenol compound derived from Curcuma longa Linn, has been recognized as a promising anti-cancer drug due to its multiple properties including antiinflammatory, anti-oxidant and anti-carcinogenic activities. To elucidate the mechanisms by which curcumin inhibits human bladder carcinoma T24 cell proliferation, we tested the effects of curcumin on specific cell cycle pathways and on the expression of cyclooxygenases (COXs). Curcumin inhibited the growth of T24 cells and induced G2/M arrest in a concentration-dependent manner, effects associated with the down-regulation of cyclin A and up-regulation of cyclindependent kinase (Cdk) inhibitor p21 (WAF1/CIP1). However, other G2/M regulatory molecules, such as cyclin A, Cdc2, Cdk2, Wee1 and Cdc25C, were not modulated by curcumin treatment. Furthermore, curcumin decreased the levels of COX-2 mRNA and protein expression without significant changes in the levels of COX-1, which correlated with a decrease in prostaglandin E2 (PGE2) synthesis. These observations suggest that curcumin may have therapeutic potential for bladder cancer patients. Introduction Cell cycle checkpoints ensure the maintenance of genomic integrity by protecting dividing cells from the potentially fatal consequences of DNA damage. The detection of DNA damage relies on a cascade of enzymes, conveying the signal(s) generated by different genotoxic stresses that block key cell cycle transitions until DNA repair has occurred (1). In the case of irreparable damage, the cells may be forced to withdraw definitively from the cell cycle or die by apoptosis so that they do not replicate or segregate chromosomes bearing unrepaired lesions. Defects in the DNA damage checkpoint and/or related cell cycle regulation network could contribute to the development of diverse types of mutations or chromosome rearrangements and promote tumorigenesis (2,3). In experimental studies, induction of cyclooxygenase (COX)-2, the enzyme catalyzing the rate-limiting step in prostaglandin biosynthesis from the substrate arachidonic acid, has been shown to promote cell growth, inhibit apoptosis and enhance cell motility (4). Moreover, compelling evidence from genetic and clinical studies indicates that COX-2 upregulation is a key step in carcinogenesis, and there is a clear positive correlation between COX-2 expression and the inhibition of cell proliferation. Overexpression of COX-2 is sufficient to cause tumorigenesis in animal models, and inhibition of the COX-2 pathway results in a reduction in tumor incidence and progression. Therefore, inhibition of COX-2 activity promises to be an effective approach in the prevention and treatment of cancer (5). Curcumin is a phenolic compound from the turmeric plant (Curcuma longa Linn, Zingiberaceae) and related species. This compound is widely used as a coloring and flavoring agent in food, and has been shown to exert a wide array of pharmacological and biological activities (6,7). To elucidate a possible mechanism of curcumin, previous studies have focused on the capability of curcumin to inhibit the growth or proliferation of human cancer cells. Curcumin interrupts the cell cycle (most often in G2/M phase), disrupts the mitotic spindle structure, and induces cell death (including apoptosis ONCOLOGY REPORTS 15: 1225-1231, 2006 Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells CHEOL PARK1*, GI YOUNG KIM2*, GUN DO KIM3, BYUNG TAE CHOI4, YEONG-MIN PARK5 and YUNG HYUN CHOI1,6 Departments of 1Biochemistry, and 2Anatomy, Dongeui University College of Oriental Medicine; 3Department of Biomaterial Control, Dongeui University Graduate School, Busan 614-052; 4School of Applied Marine Science, College of Ocean Science, Cheju National University, Jeju 690-756; 5Department of Microbiology, College of Natural Sciences, Kukyong National University, Busan 608-737; 6Department of Microbiology and Immunology, and Laboratory of Dendritic Cell Differentiation and Regulation, Pusan National University College of Medicine, Busan 602-739, Korea Received November 1, 2005; Accepted December 21, 2005 _________________________________________ Correspondence to: Dr Yung Hyun Choi, Department of Biochemistry, Dongeui University College of Oriental Medicine, Busan 614-052, Korea E-mail: choiyh@deu.ac.kr Dr Yeong-Min Park, Department of Microbiology and Immunology, Pusan National University College of Medicine, Busan 602-739,